For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Genpact Ltd. (G) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-14): Designation Gem · Cairn score +45 (−100…+100 Quality+Value blend) · Quality 62 · Value 31 · Sentiment -17 (timing only, not weighted) · Composite fair value $57.16 vs $33.93 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Genpact Ltd.
G NYSEGenpact Ltd. is a global professional services and technology company specializing in digitally enabled business process management and transformation. The company designs, runs, and optimizes operations for enterprises across sectors such as banking and financial services, insurance, capital markets, consumer packaged goods, life sciences, healthcare, manufacturing, and high tech. Genpact’s offerings span digital operations, finance and accounting services, sourcing and procurement, risk and compliance, supply chain, customer service, and human resources. It also provides technology services including application development and management, cloud and data engineering, analytics, and artificial intelligence solutions tailored to industry-specific needs. By combining domain expertise with data-driven insights and automation, Genpact helps organizations streamline workflows, improve decision-making, and modernize legacy processes. The firm serves clients globally and generates a significant portion of its revenue from India. Founded in 1997 and headquartered in Hamilton, Bermuda, Genpact plays a notable role in the information technology services and business process outsourcing market.
Earnings Schedule
Checked daily · calendar updated Aug 14| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $0.97 | $1.00 +3.1% | — | — |
| May 7, 2026 | $0.92 | $0.98 +6.5% | — | — |
| Mar 13, 2026 | $1.51 | $1.59 +5.3% | — | — |
| Feb 5, 2026 | $0.93 | $0.97 +4.3% | — | — |
| Nov 6, 2025 | $0.90 | $0.97 +7.8% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 13, 2026 | 144 | View |
| Aug 13, 2026 | 4 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | View |
| Aug 12, 2026 | 144 | View |
| Aug 11, 2026 | 144 | View |
| Aug 7, 2026 | 10-Q | View |
| Aug 6, 2026 | 8-K | View |
| Jul 31, 2026 | SCHEDULE 13G/A | View |
| Jul 8, 2026 | SCHEDULE 13G/A | View |
| May 15, 2026 | SCHEDULE 13G | View |
| May 8, 2026 | 10-Q | View |
| May 7, 2026 | 8-K | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.13
Total Equity: $2.55B
Shares: 176,646,644
Total Debt: $1.54B
Cash: $853.84M
EBITDA: $820.87M
Total Debt: $1.54B
Cash: $853.84M
Revenue: $5.08B
Revenue: $5.08B
Revenue: $5.08B
Total Equity: $2.55B
Tax Rate: 24.3%
Equity: $2.55B
Total Debt: $1.54B
Cash: $853.84M
Current Liabilities: $1.60B
Long-Term Debt: $1.17B
Total Debt: $1.54B
Total Equity: $2.55B
Shares: 176,646,644
Shares: 176,646,644
CapEx: -$78.20M
Shares: 176,646,644
Stock Price: $33.97
Net Income: $552.49M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 12, 2026 1:19pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.4B | $4.5B | $4.8B | $5.1B |
| Cost of Revenue | $2.6B | $2.8B | $2.9B | $3.1B | $3.2B |
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.7B | $1.8B |
| Operating Expenses | $923.0M | $1.0B | $939.8M | $988.0M | $1.1B |
| Operating Income | $509.0M | $502.2M | $630.9M | $702.1M | $750.2M |
| Net Income | $369.4M | $353.4M | $631.3M | $513.7M | $552.5M |
| EBITDA | $618.1M | $589.0M | $703.4M | $771.8M | $820.9M |
| EPS | $1.97 | $1.92 | $3.46 | $2.88 | $3.18 |
| EPS (Diluted) | $1.91 | $1.88 | $3.41 | $2.85 | $3.13 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 4:51pm (10d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $899.5M | $646.8M | $583.7M | $648.2M | $853.8M |
| Total Current Assets | $1.9B | $1.8B | $1.9B | $2.1B | $2.7B |
| Total Assets | $5.0B | $4.6B | $4.8B | $5.0B | $5.8B |
| Current Liabilities | $1.3B | $1.1B | $1.3B | $963.7M | $1.6B |
| Long-Term Debt | $1.3B | $1.2B | $824.7M | $1.2B | $1.2B |
| Total Liabilities | $3.1B | $2.8B | $2.6B | $2.6B | $3.3B |
| Total Equity | $1.9B | $1.8B | $2.2B | $2.4B | $2.5B |
| Retained Earnings | $732.5M | $780.0M | $1.1B | $1.2B | $1.4B |
Cash Flow (Annual)
Last updated: Aug 12, 2026 1:19pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $694.3M | $443.7M | $490.8M | $615.4M | $812.9M |
| Capital Expenditure | -$53.3M | -$50.6M | -$55.4M | -$82.8M | -$78.2M |
| Free Cash Flow | $640.9M | $393.1M | $435.4M | $532.7M | $734.7M |
| Acquisitions (net) | -$72.0M | $-33,000 | $-682,000 | $0 | -$80.4M |
| Net Debt Issued / (Repaid) | $316.0M | -$381.0M | -$19.9M | -$33.1M | $323.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$298.2M | -$214.1M | -$225.5M | -$252.7M | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 12, 2026 1:19pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +8.7% | +2.4% | +6.5% | +6.6% |
| Gross Profit Growth | +7.3% | +2.2% | +7.6% | +8.3% |
| Operating Income Growth | -1.3% | +25.6% | +11.3% | +6.9% |
| Net Income Growth | -4.3% | +78.6% | -18.6% | +7.6% |
| EBITDA Growth | -4.7% | +19.4% | +9.7% | +6.4% |
Dividend History (Last 20)
Last updated: Aug 12, 2026 12:58pm (1d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-10 | $0.19 | — | — | — |
| 2026-03-16 | $0.19 | — | — | — |
| 2025-09-11 | $0.17 | — | — | — |
| 2025-06-18 | $0.17 | — | — | — |
| 2025-03-11 | $0.17 | — | — | — |
| 2024-12-09 | $0.15 | — | — | — |
| 2024-09-11 | $0.15 | — | — | — |
| 2024-06-10 | $0.15 | — | — | — |
| 2024-03-08 | $0.15 | — | — | — |
| 2023-12-07 | $0.14 | — | — | — |
| 2023-09-07 | $0.14 | — | — | — |
| 2023-06-08 | $0.14 | — | — | — |
| 2023-03-09 | $0.14 | — | — | — |
| 2022-12-08 | $0.13 | — | — | — |
| 2022-09-08 | $0.13 | — | — | — |
| 2022-06-09 | $0.13 | — | — | — |
| 2022-03-09 | $0.13 | — | — | — |
| 2021-12-09 | $0.11 | — | — | — |
| 2021-09-09 | $0.11 | — | — | — |
| 2021-06-10 | $0.11 | — | — | — |
Insider Trading (Recent)
Last updated: Aug 12, 2026 1:14pm (1d ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-23 | Hinshaw John M | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Morken CeCelia | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Lindstrom Carol | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Gangestad Nicholas C | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Subaiya Thimaya K. | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Verdi Mark A | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | STEVENS BRIAN MARK | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Conigliaro Laura | A-Award | 6,521.00 | $0.00 | $0 |
| 2026-04-23 | Madden James C. | A-Award | 9,999.00 | $0.00 | $0 |
| 2026-03-10 | Weiner Michael Hal | F-InKind | 7,019.00 | $38.92 | $273,179 |
| 2026-03-10 | Vashisht Riju | F-InKind | 7,080.00 | $38.92 | $275,554 |
| 2026-03-10 | Nanduru Anil | F-InKind | 7,663.00 | $38.92 | $298,244 |
| 2026-03-10 | Mehta Piyush | F-InKind | 5,702.00 | $38.92 | $221,922 |
| 2026-03-10 | Dewan Sameer | F-InKind | 3,542.00 | $38.92 | $137,855 |
| 2026-03-10 | Kalra Balkrishan | F-InKind | 13,893.00 | $38.92 | $540,716 |
| 2026-03-04 | Kalra Balkrishan | M-OptionExercise | 2,800.00 | $0.00 | $0 |
| 2026-03-04 | Kalra Balkrishan | S-Sale | 2,800.00 | $40.77 | $114,156 |
| 2026-03-03 | Kalra Balkrishan | A-Award | 27,160.00 | $0.00 | $0 |
| 2026-03-03 | Dewan Sameer | A-Award | 6,928.00 | $0.00 | $0 |
| 2026-03-03 | Mehta Piyush | A-Award | 14,618.00 | $0.00 | $0 |
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-14 01:29| Case | Growth | Margin | Fair value | vs price ($33.93) |
|---|---|---|---|---|
| Bull — recovery | +11% | 12.8% | $65.74 | +94% |
| Base — stabilizes | +7% | 11.1% | $51.36 | +51% |
| Bear — keeps slipping | +4% | 9.4% | $39.33 | +16% |
| Stress — last quarter repeats | +7% | 11.2% | $50.89 | +50% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-12Genpact already owns the process, the SLAs, the exception paths and the change-management relationship inside ~thousands of enterprise workflows — the least glamorous, hardest-to-acquire part of deploying agents at an enterprise. If it re-prices to outcomes/transactions, it can deliver the same work with a fraction of the 125k-plus delivery base and keep the spread for a few renewal cycles.
The monetized unit is effectively FTE-linked. Every productivity gain becomes a client-visible savings claim at rebid, so AI shows up first as price-per-transaction deflation rather than margin. That is exactly the mechanism behind 2-3% organic growth and the -3.9% share gap versus a 10.5%-growing industry.
Whether Genpact converts a majority of revenue to outcome/transaction/consumption pricing BEFORE clients force productivity share-back on FTE contracts. Observable: disclosed share of non-FTE-priced bookings, revenue-per-employee trend, and headcount falling while revenue grows.
Regulated, liability-bearing operations run under contract — KYC/AML, claims adjudication, statutory close, pharmacovigilance — plus decades of client-specific exception logic and audit trails no enterprise wants to re-own. Enterprise procurement trust and multi-year embedded contracts are slower to copy than the software.
AI Lens thesis
Genpact's job — run someone else's back office better and cheaper than they can — survives cheap intelligence completely; its delivery model does not. Labor arbitrage was the scarce asset, and AI makes the arbitraged input abundant, so the price of a processed invoice, claim, or ticket falls toward the cost of inference. Genpact's defense is that it holds the messy last mile: exception handling, regulatory accountability, integration into a client's specific ERP mess, and a client base that genuinely does not want to own compliance operations. That shield is real but thinner than PAYC's, because Genpact is not a system of record — SAP, Oracle, Workday and ServiceNow can embed agents directly in the system where the transaction lives and route around the BPO layer, and AI-native service startups can bid per-outcome with no labor base to defend. Structurally: revenue-per-employee rises, revenue-per-process falls, and whether the two cross positively decides the next five years.
What the market may be underestimating
Upside Agentic deployment inside large enterprises stalls on data plumbing, exception governance and accountability — precisely the labor Genpact already performs. It could become the paid integrator/operator of other vendors' agents, converting a shrinking labor pool into a higher-margin operations-management annuity.
Downside The deflation may land asymmetrically on the highest-margin, most standardized work (F&A, procurement, order-to-cash) first, leaving Genpact holding the low-margin, unautomatable residue — a mix shift that compresses margins even if headline revenue holds.
Outcome range spread 48 · unresolved
Claude Reading
The raw print is cleaner than the models want to admit. Q1 2026 revenue of $1.30B is up 7.4% YoY from $1.21B in Q1 2025, and quarterly net margin has held in a tight 10.4–11.4% band across eight quarters — no compression visible in the tape. Full-year 2025 revenue of $5.08B grew 6.5% over 2024's $4.77B, operating income expanded from $702M to $750M (op margin 14.8% vs 14.7%, essentially flat, not the "320bp compression" the bear thesis alleges), and net income grew 7.6%. FCF of $735M on a $5.71B market cap is a 12.9% FCF yield, and capex is a trivial $78M — this is not a business needing to reinvest to defend its base. Debt/equity of 0.6 with $854M cash against $1.54B debt is unremarkable for a services roll-up. ROE 21.7%, ROIC 17.5%. These are not the numbers of a franchise in structural decline; they are the numbers of a franchise the market has decided is in structural decline.
Where I part ways with the Market Forces model: it asserts "margin compression, market share losses, and insider silence" as though these are established facts. Margins are flat-to-up sequentially. Revenue growth accelerated from 4.6% in 2023 to 6.5% in 2025. And the insider table shows April 2026 award grants — routine RSU vesting, not "silence" and not a sell signal. Market Forces is telling a story the numbers don't corroborate. The Thesis Evaluation's -12 score leans heavily on "generative AI makes labor arbitrage BPO structurally obsolete within 5 years" at 75/100 weight — a plausible narrative but one that has been leveled at Genpact, Cognizant, Infosys, and WNS for three years while all of them have kept growing. If AI displacement were biting, you'd see it in the sequential margin line first; you don't. I side with the Valuation Synthesis directionally, though its $56 fair value looks generous — 10x FCF of $735M puts EV around $7.35B, less $687M net debt = ~$6.66B equity or ~$39/share on a no-growth basis, and 12x gets you to ~$48. Fair value band $42–$52, not $56.
The contrarian case worth taking seriously isn't "AI kills BPO in 5 years" — it's more mundane: revenue growth is decelerating on a two-year stack (Q4 2025 rev $1.32B vs Q3 $1.29B and Q1 2026 $1.30B — essentially flat for three quarters), and the 6.5% CAGR is inflated by wage pass-throughs and FX rather than volume. If book-to-bill is softening (not disclosed here), the 2026 exit rate could print $5.3B rather than $5.4B, which would collapse the "growth is free" thesis. Second, EPS growth has depended on buybacks — net income CAGR of -6.5% over 5 years is misleading due to the 2023 tax-driven $631M NI spike, but even normalizing, earnings growth is single-digit and comes partly from share count reduction, which requires the FCF to keep flowing. Third, EV/EBITDA of 7.9x is cheap only if you believe EBITDA is defensible; peers EXLS trade richer precisely because their analytics mix is perceived as more defensible than Genpact's finance-and-accounting-heavy book. The data is thin on segment mix and client concentration, which is where the real answer lives.
Net: I dissent from Market Forces and from the Thesis Evaluation's negative score, and partially agree with the Valuation Synthesis. At $33.97 you are paying 10.9x earnings and 7.8x EV/EBITDA for a business compounding revenue mid-single-digits, generating a 13% FCF yield, returning cash via a 2.1% dividend plus buybacks, with ROIC of 17.5% and no visible operational deterioration in eight quarters of data. The bear thesis requires forward deterioration that isn't yet in the numbers. Even if you assign a 30% probability to the "AI kills BPO" scenario and haircut FCF by 40%, blended fair value still sits above $40. The narrative model is right that there's no story premium here — that's precisely the setup where fundamentals mean-revert once one or two quarters of stable prints accumulate. Starter position at $34, add on any dip toward $30, exit band $45–$50.
GPT Reading
What stands out is how ordinary-and-good the operating story is versus how cheap the stock is priced. Revenue has climbed from $4.02B in 2021 to $5.08B in 2025, a 6%+ CAGR, and the quarterly run-rate now sits around $1.30B versus $1.18B a year earlier in the comparable quarter. That is not a melting-ice-cube profile. Net income has also become steadier: the last five quarters are tightly clustered between $131M and $148M, with net margins holding around 10.6%-11.4%. Operating income reached $750M in 2025 on a 14.8% operating margin, up from $702M in 2024 and $631M in 2023. For a company the market seems to view as an ex-growth outsourcing franchise under existential AI pressure, the actual numbers show a business still growing, still earning, and not yet conceding economics.
The bigger tell is cash generation. 2025 free cash flow was $734.7M against a $5.71B market cap, an FCF yield of roughly 12.9%. Operating cash flow was $812.9M versus net income of $552.5M, which suggests earnings quality is better than the P&L alone implies. With capex only $78.2M, this remains a capital-light services model that turns profit into cash. Balance sheet risk also looks manageable: $1.54B of debt offset by $853.8M of cash leaves net debt around $690M, less than one year of free cash flow. On that base, 10.9x earnings, 7.9x EV/EBITDA, and 1.18x sales feel too low for a company delivering mid-single-digit growth with 20%+ ROE and 17.5% ROIC. If Genpact merely sustains the current earnings base, the stock looks mispriced; if it compounds even modestly, it looks clearly undervalued.
I also think some of the more bearish model language overreaches the evidence. The claim that this is a “deteriorating BPO franchise” does not fit a sequence where annual revenue rose from $4.77B to $5.08B and annual net income from $513.7M to $552.5M, while the most recent quarter posted 6.6% revenue growth and 7.6% earnings growth. Likewise, the margin-compression fear is not visible in the presented data: quarterly net margins have been remarkably stable, and annual operating margin improved from 14.7% in 2024 to 14.8% in 2025 after rising sharply from 11.5% in 2022. This is not a business currently showing the accounting fingerprints of structural collapse. The market may be discounting future AI disintermediation, but today’s valuation already prices in a lot of that risk as though the decline has begun in earnest.
The best bear case is that the market is correctly valuing Genpact as a no-mo services company before the slowdown becomes obvious in reported numbers. A 6%-7% top-line CAGR is not special for tech services, and the 2023 net income figure of $631.3M being well above 2024 and 2025 reminds you earnings power is not strictly linear. The company operates in a people-intensive industry where pricing can erode fast if clients push automation, consolidate vendors, or repatriate processes. If AI reduces demand for labor-based process work faster than Genpact can reposition into higher-value transformation services, then today’s 13% FCF yield may be a value trap rather than a bargain. The lack of meaningful open-market insider buying does not help the bull case either; the transaction list is basically awards and in-kind activity, not executives stepping in at $34.
What would change my mind is not abstract AI rhetoric but specific deterioration in the numbers. If quarterly revenue growth slips from the current mid-single digits to flat or negative while net margin falls below 10% for multiple quarters, the low multiple would make more sense. If annual free cash flow drops materially below $600M without a corresponding strategic reinvestment case, I would stop treating the cash yield as durable. Conversely, if Genpact can keep revenue around a $5.3B-$5.4B annualized pace, hold operating margin near 14.5%-15%, and continue producing $700M+ of FCF, I would expect the stock to migrate toward at least 12x-13x earnings, which implies something in the low-to-mid $40s rather than $34.
Grok Reading
The numbers describe a durable cash compounder the market has decided to treat like a melting ice cube. Genpact put up $5.08B of revenue in 2025, up from $4.77B and $4.48B the two prior years, a clean 6.5% revenue CAGR that has not broken. Net margins have sat in a tight 10.4–11.4% band for eight straight quarters; the latest print was $1.30B revenue and $148M of net income at 11.4%. Operating margin expanded from roughly 11.5% in 2022 to 14.8% in 2025. Free cash flow of $734.7M on an $5.71B equity value is a 12.9% FCF yield, with capex a trivial $78M, so almost every dollar of operating cash converts. ROE at 21.7% and ROIC at 17.5% are not the profile of a franchise in structural freefall. At 10.9x earnings, 7.9x EV/EBITDA and 1.18x sales, the stock is priced as if that cash stream is already shrinking. It is not.
What stands out hardest is the gap between the deterioration narrative and the actual series. The −6.5% earnings CAGR is an artifact of the 2023 NI spike to $631M; run the same line from 2021 ($369M) to 2025 ($553M) and earnings compounded positively. Quarterly revenue is still advancing year-on-year in the mid-single digits, not rolling over. Debt of $1.54B against $854M cash and $2.55B equity is manageable (D/E 0.60), and the 2.1% dividend is covered several times over by FCF. The valuation work that lands near $50–56 is directionally right: a no-growth perpetuity on current FCF already clears the current $33.97 price, so the 6% top-line growth and any AI-services mix shift are effectively free. The market is not applying a narrative premium or discount so much as embedding a terminal-decline assumption the income statement has refused to validate for four years.
The cleanest bear case is real and must be weighed. Generative AI can automate large slices of the labor-arbitrage work that built this franchise; if clients insource or rebid aggressively, the 6% growth rate can go to 2% and the mid-teens operating margin can compress several hundred basis points. Peers with cleaner digital stories (EXLS, CTSH) still clear mid-to-high teens earnings multiples, which implies the market has already sorted Genpact into the “legacy BPO” bucket and will not re-rate on hope. A single large-client loss or a guidance cut that confirms pricing pressure would validate that sorting. I weigh this less heavily today because the margin and FCF data have not yet shown the compression the thesis requires, and because Genpact’s installed base and process IP give it a multi-year window to sell AI-augmented delivery rather than pure headcount. The bear case is a plausible five-year path, not a present fact in the financials.
I would flip to a more cautious or negative stance if trailing-twelve-month revenue growth falls through 3% for two consecutive quarters, if operating margin breaks below 13% on a run-rate basis, or if FCF drops under $500M without an obvious one-time working-capital explanation. A large contract loss disclosed in a 10-Q or a peer takeout at a low multiple that resets the entire BPM valuation grid would also force a reset. Conversely, two quarters of organic growth re-accelerating through 8% with stable or rising margins would argue the AI-services pivot is landing and the multiple can expand toward the mid-teens, making the current entry look even cheaper.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · four lenses
Revenue has climbed every year from 4.02B in 2021 to 5.08B in 2025 (about 6% CAGR), with gross margin stable around 35-36% and operating margin expanding from 12.7% to 14.8%. Net income is 552.5M and FCF hit 734.7M in 2025, up from 640.9M in 2021, with OCF/NI at 1.32x and accruals at -2.4% of assets - cash conversion is genuine, not accounting-driven. Beneish M at -2.72 and clean accruals leave no earnings-quality red flags. Capital allocation is shareholder-friendly: diluted share count fell from 193.0M to 176.6M (a -2.2% CAGR), SBC is a modest 1.8% of revenue, and buybacks run 2.45x SBC, so per-share value is being concentrated. Balance sheet is a mild constraint rather than a cushion - 1.20B liquid cash but -338.5M net cash and an Altman Z of 2.88 (grey zone) - but 734.7M annual FCF trivially services this. Insider tape shows only routine grants and tax withholdings, no open-market P/S signal in either direction. Overall this reads as a mature, well-run services franchise with modest but real margin expansion and disciplined capital return.
Verify before trusting this (6)
- Customer concentration and any large-client renewal risk in the 10-K
- Composition of debt (maturities, rates) versus the 1.20B cash
- Segment mix between Data-Tech-AI and Digital Operations, and pricing trends
- Nature of the 2023 net income spike (one-time gain or tax benefit?)
- Exposure to GenAI-driven labor displacement and management commentary on same
- Any contingent liabilities or client dispute disclosures
The e2e composite pegs fair value at $56.15 with a signal-adjusted $50.00, implying 47% upside from $33.93. Sanity-checking the inputs: the DCF at $69.45 looks aggressive for a 2-6% organic grower and I discount it; the EPV floor at $44.60 and anchored-PE at $41.08 are the more grounded anchors and both sit meaningfully above the current price. Blending toward the more conservative anchors, deserved value lands in the low-to-mid $40s, giving roughly 20-30% margin of safety - modest, not deep. Earnings quality is high and the Company-Quality lens grades Strong, so I do not haircut deserved value further. What is priced in at $33.93 is a story of BPM commoditization, in-house AI substitution, and stalled organic growth. That is a plausible bear case but the financial evidence - 200+ bps of margin expansion, OCF above net income, shrinking share count, real FCF - argues the market is over-discounting a disciplined compounder. The gap is real but not the kind of dislocation that demands aggressive sizing; it is a reasonable-price entry on a decent business, which is a legitimate mispricing but a common one.
Verify before trusting this (5)
- Organic constant-currency revenue growth trajectory in next 2 quarters
- Operating margin guidance and evidence AI is expanding or eroding gross margin
- Bookings/backlog and large-deal signings vs prior year
- Buyback pace and net debt trend
- Any client concentration or vertical (BFSI) softness commentary
Genpact is the definition of a low-narrative-pressure stock right now. Archetype is quiet-quality with minimal intensity and low cult coefficient, meaning there is essentially no story momentum pulling the tape - neither an AI-services mania lifting it nor a collapsing bull thesis crushing it. With beta 0.58, the mildly risk-on regime (score +47, VIX 15.3) barely reaches this name; defensive IT services simply do not participate much in tape-driven moves in either direction. The recent press cycle is quietly constructive: two post-earnings pieces framing the stock as 'undervalued' and highlighting raised guidance and 24% growth in Advanced Technology Solutions. That is a low-wattage tailwind - the kind of coverage that supports a floor but does not ignite buyers, especially given the 5% sell-the-news drop on the actual print. The overhang is thematic: the market's active AI narrative treats BPM/outsourcing as structurally threatened (clients build AI in-house), which caps multiple expansion even when numbers are good. Analyst tone is not euphoric, targets are not being aggressively revised up, and the stock's five-year -30% drift confirms the market's disinterest. Net: a modest positive news drip against a persistent thematic skepticism, in a tape too calm to matter much. Pressure is close to neutral, leaning barely positive.
Verify before trusting this (4)
- Whether sell-side target revisions actually move up after the raised guide or stay flat (tone divergence)
- Any sector rotation into defensive/value IT services that could wake the cohort
- Fresh narrative catalyst - an AI-services partnership or big deal - that would give the story something to grab
- Follow-through in price over the next 2-4 weeks; a failure to hold post-earnings levels would confirm the thematic overhang is dominant
Genpact's job — run someone else's back office better and cheaper than they can — survives cheap intelligence completely; its delivery model does not. Labor arbitrage was the scarce asset, and AI makes the arbitraged input abundant, so the price of a processed invoice, claim, or ticket falls toward the cost of inference. Genpact's defense is that it holds the messy last mile: exception handling, regulatory accountability, integration into a client's specific ERP mess, and a client base that genuinely does not want to own compliance operations. That shield is real but thinner than PAYC's, because Genpact is not a system of record — SAP, Oracle, Workday and ServiceNow can embed agents directly in the system where the transaction lives and route around the BPO layer, and AI-native service startups can bid per-outcome with no labor base to defend. Structurally: revenue-per-employee rises, revenue-per-process falls, and whether the two cross positively decides the next five years.
Verify before trusting this (8)
- Per-transaction pricing at rebid
- Client-mandated AI savings clauses
- Gross margin direction vs 36%
- Disclosed non-FTE pricing mix
- Total contract value versus headcount
- Organic growth versus industry 10.5%
- Revenue per employee trajectory
- Headcount vs revenue divergence